Erlen Takes Over as New Schering AG CEO

Vita Appointed Chairman of Supervisory Board



Apr 30, 2001, 01:00 ET from Schering AG

    BERLIN, Germany, April 30 /PRNewswire/ -- Schering AG (NYSE:   SHR)
 announced that Dr. Hubertus Erlen has assumed the chairmanship of the
 Executive Board of Schering AG, following its Annual General Meeting,
 succeeding Dr. Giuseppe Vita, who retired after 12 years as chairman.  The
 Supervisory Board of Schering AG appointed Dr. Giuseppe Vita as its new
 chairman, and Dr. Mathias Dopfner, a member of the Executive Board of
 Axel-Springer-Verlag AG Berlin, and Hermann-Josef Lamberti, member of the
 Executive Board of Deutsche Bank AG Frankfurt/Main, as new members of the
 Supervisory Board.
 
     Schering AG is a research-based pharmaceutical company.  Its activities
 are focused on four business areas: Fertility Control and Hormone Therapy,
 Diagnostics and Radio-pharmaceuticals, Dermatology as well as Therapeutics for
 disabling diseases, e.g. multiple sclerosis, leukemia and solid tumors.  As a
 global player with innovative products Schering AG aims for leading positions
 in specialized markets worldwide.
 
     For further information please contact:
     * Jane Kramer, Public Affairs, 973/487-2246
     * Joanne Marion, U.S. Investor Relations, 973/487-2164
     * Dr. Friedrich von Heyl - Business and Financial Communication:
       Tel.: +49-30-468 152 96;Fax: +49-30-468 166 46; eMail:
       friedrich.vonheyl@schering.de
     * Peter Vogt - Investor Relations: Tel.: +49-30-468 128 38;
       Fax: +49-30-468 166 46; eMail: peter.vogt@schering.de
 
     Certain statements in this press release that are neither reported
 financial results nor other historical information are forward-looking
 statements, including but not limited to, statements that are predictions of
 or indicate future events, trends, plans or objectives.  Undue reliance should
 not be placed on such statements because, by their nature, they are subject to
 known and unknown risks and uncertainties and can be affected by other factors
 that could cause actual results and Schering AG's plans and objectives to
 differ materially from those expressed or implied in the forward-looking
 statements.  Certain factors that may cause such differences are discussed in
 our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange
 Commission.  Schering AG undertakes no obligation to update publicly or revise
 any of these forward-looking statements, whether to reflect new information or
 future events or circumstances or otherwise.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X85275556
 
 

SOURCE Schering AG
    BERLIN, Germany, April 30 /PRNewswire/ -- Schering AG (NYSE:   SHR)
 announced that Dr. Hubertus Erlen has assumed the chairmanship of the
 Executive Board of Schering AG, following its Annual General Meeting,
 succeeding Dr. Giuseppe Vita, who retired after 12 years as chairman.  The
 Supervisory Board of Schering AG appointed Dr. Giuseppe Vita as its new
 chairman, and Dr. Mathias Dopfner, a member of the Executive Board of
 Axel-Springer-Verlag AG Berlin, and Hermann-Josef Lamberti, member of the
 Executive Board of Deutsche Bank AG Frankfurt/Main, as new members of the
 Supervisory Board.
 
     Schering AG is a research-based pharmaceutical company.  Its activities
 are focused on four business areas: Fertility Control and Hormone Therapy,
 Diagnostics and Radio-pharmaceuticals, Dermatology as well as Therapeutics for
 disabling diseases, e.g. multiple sclerosis, leukemia and solid tumors.  As a
 global player with innovative products Schering AG aims for leading positions
 in specialized markets worldwide.
 
     For further information please contact:
     * Jane Kramer, Public Affairs, 973/487-2246
     * Joanne Marion, U.S. Investor Relations, 973/487-2164
     * Dr. Friedrich von Heyl - Business and Financial Communication:
       Tel.: +49-30-468 152 96;Fax: +49-30-468 166 46; eMail:
       friedrich.vonheyl@schering.de
     * Peter Vogt - Investor Relations: Tel.: +49-30-468 128 38;
       Fax: +49-30-468 166 46; eMail: peter.vogt@schering.de
 
     Certain statements in this press release that are neither reported
 financial results nor other historical information are forward-looking
 statements, including but not limited to, statements that are predictions of
 or indicate future events, trends, plans or objectives.  Undue reliance should
 not be placed on such statements because, by their nature, they are subject to
 known and unknown risks and uncertainties and can be affected by other factors
 that could cause actual results and Schering AG's plans and objectives to
 differ materially from those expressed or implied in the forward-looking
 statements.  Certain factors that may cause such differences are discussed in
 our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange
 Commission.  Schering AG undertakes no obligation to update publicly or revise
 any of these forward-looking statements, whether to reflect new information or
 future events or circumstances or otherwise.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X85275556
 
 SOURCE  Schering AG